Sign in
Taking people in United StatesPhase 1/2

Tests VS-7375 in adults with advanced solid tumors carrying a KRAS G12D mutation

Tests the drug VS-7375, alone or combined, in adults with advanced KRAS G12D-mutated cancers.

Key facts

Who runs it
Verastem, Inc.
Where
Ann Arbor, Baltimore, Boston, Charlottesville, Fairfax, Houston, Los Angeles, Nashville, New York, Philadelphia, Salt Lake City, Seattle, and St Louis, United StatesSee the 13 sitesAlso in 3 other countries, 9 sites
Trial code
Registry title
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
Status
Recruiting
Phase
Phase 1/2
People taking part
616 people, planned
Started
24 Jun 2025
Expected to end
Dec 2028
Type of study
Interventional, 14 groups
Treatments tested
  • VS-7375
  • Cetuximab
  • Carboplatin + Pemetrexed + Pembrolizumab
  • Gemcitabine + Nab-paclitaxel
  • Pembrolizumab
  • Defactinib
  • Midazolam
  • Repaglinide
Record updated
10 November 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with an advanced solid tumor that carries a KRAS G12D mutation and cannot be removed by surgery or has spread.

Age
18 years or older
Sex
All sexes can join
Disease stage
Locally advanced tumor that cannot be removed by surgery, or metastatic solid tumor. The disease must be measurable (RECIST v1.1). ECOG performance status 0 or 1.
Earlier treatment
People who had direct RAS inhibitors cannot join. Chemotherapy, targeted therapy, radiotherapy or immunotherapy within 4 weeks before starting is not allowed. Side effects from earlier treatment must have recovered to Grade 1 or less, or to baseline.
Biomarker or test result
The tumor must carry a KRAS G12D mutation.

Main reasons for not taking part

  • Previous treatment with direct RAS inhibitors
  • Brain metastases that cause symptoms, are untreated or are growing
  • Cannot swallow oral medicines
  • Uncontrolled, clinically significant serious disease (for example heart, kidney, liver or autoimmune disease)
  • Pregnant or breastfeeding

The registry criteria, word for word

Show all 17 criteriaShow less

Who can take part

  • Individuals ≥18 years of age
  • Agreement to sign and date an informed consent form (ICF) approved by the Institutional Review Board (IRB)/Independent Ethics Committee (IEC)
  • Histologic or cytologic evidence of locally advanced unresectable or metastatic solid tumor harboring a KRAS G12D mutation
  • Measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
  • Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
  • Adequate organ function
  • Adequate cardiac function
  • Recovered from all AEs due to previous therapies to Grade ≤1 or baseline
  • Agreement to use highly effective contraception

Who cannot take part

  • Underwent major surgical procedure as defined by the Investigator, other than for diagnosis, within 4 weeks prior to Cycle 1 Day 1
  • Receipt of chemotherapy, targeted therapy, or radiotherapy (excluding palliative radiation) within 4 weeks or 5 half-lives, whichever is shorter, or immunotherapy within 4 weeks prior to Cycle 1 Day 1
  • Treatment with any investigational drug at least 4 weeks or 5 half-lives, whichever is shorter, prior to Cycle 1 Day 1
  • History of treatment with direct RAS inhibitors
  • Inability to swallow oral medications
  • Evidence or history of uncontrolled, clinically significant hematological, renal, hepatic, endocrine, pulmonary, gastrointestinal, cardiovascular, psychiatric, coagulation, neurologic, dermatologic, autoimmune, or allergic disease
  • Symptomatic, untreated, or actively progressing known central nervous system (CNS) metastases
  • Individuals who are pregnant or breastfeeding

Where in United States

Also in 3 other countries, 9 sites

  • University of MichiganAnn Arbor, United StatesContact: Vaibhav Sahai, MDTaking people
  • Johns Hopkins UniversityBaltimore, United StatesContact: Nilofer AzadTaking people
  • Massachusetts General HospitalBoston, United StatesContact: Leon Pappas, MDTaking people
  • University of VirginiaCharlottesville, United StatesContact: Polly WuTaking people
  • Virginia Cancer SpecialistsFairfax, United StatesContact: Carrie Friedman, RN, BSN, OCNTaking people
  • MD Anderson Cancer CenterHouston, United StatesContact: Ly M NguyenTaking people
  • Cedars-Sinai Medical CenterLos Angeles, United StatesContact: Arsen Osipov, MD (principal investigator)Taking people
  • SCRI Oncology PartnersNashville, United StatesContact: SCRI Referral TeamTaking people
  • Laura & Isaac Perlmutter Cancer Center at NYU LangoneNew York, United StatesContact: Jennifer CoffeyTaking people
  • Univ of Pennsylvania, Abramson Cancer CenterPhiladelphia, United StatesContact: Mark O'Hara, MDTaking people
  • Huntsman Cancer InstituteSalt Lake City, United StatesContact: Susan SharryTaking people
  • Virginia Mason Medical CenterSeattle, United StatesContact: Priscilla KimTaking people
  • Washington University School of MedicineSt Louis, United StatesContact: Sara MitchumTaking people

About the trial

What the trial wants to find out

This study will assess the safety and efficacy of VS-7375 alone and in combination in patients with advanced solid tumors harboring a KRAS G12D-mutation.

The 14 groups in the trial

  • VS-7375 Monotherapy Dose EscalationTreatment being tested

    To characterize the safety and tolerability of escalating doses of VS-7375 as monotherapy and to determine the recommended phase 2 dose (RP2Ds) in patients with advanced solid tumors harboring KRAS G12D mutation.

    Treatment: VS-7375

  • VS-7375 Monotherapy Dose Expansion - PDACTreatment being tested

    To evaluate the efficacy of VS-7375 at the recommended phase 2 dose (RP2Ds) in patients with metastatic PDAC harboring KRAS G12D-mutation.

    Treatment: VS-7375

  • VS-7375 Monotherapy Dose Expansion - NSCLCTreatment being tested

    To evaluate the efficacy of VS-7375 at the recommended phase 2 dose (RP2Ds) in patients with metastatic NSCLC harboring KRAS G12D-mutation.

    Treatment: VS-7375

  • VS-7375 Monotherapy Dose Expansion - Solid TumorsTreatment being tested

    To evaluate the efficacy of VS-7375 at the recommended phase 2 dose (RP2Ds) in patients with metastatic solid tumors harboring KRAS G12D-mutation.

    Treatment: VS-7375

  • VS-7375 + Cetuximab Dose EscalationTreatment being tested

    To characterize the safety and tolerability of escalating doses of VS-7375 in combination with cetuximab and to determine the recommended phase 2 dose (RP2Ds) in patients with advanced or metastatic PDAC, BTC, CRC harboring KRAS G12D-mutation.

    Treatment: VS-7375 and Cetuximab

  • VS-7375 + Carboplatin/Pemetrexed/Pembrolizumab Dose EscalationTreatment being tested

    To characterize the safety and tolerability of escalating doses of VS-7375 in combination with carboplatin/pemetrexed/pembrolizumab and to determine the recommended phase 2 dose (RP2Ds) in patients with metastatic NSCLC harboring KRAS G12D-mutation.

    Treatment: VS-7375 and Carboplatin + Pemetrexed + Pembrolizumab

  • VS-7375 + Gemcitabine/Nab-Paclitaxel Dose EscalationTreatment being tested

    To characterize the safety and tolerability of escalating doses of VS-7375 in combination with gemcitabine/nab-paclitaxel and to determine the recommended phase 2 dose (RP2Ds) in patients with advanced or metastatic PDAC harboring KRAS G12D-mutation.

    Treatment: VS-7375 and Gemcitabine + Nab-paclitaxel

  • VS-7375 + Pembrolizumab Dose EscalationTreatment being tested

    To characterize the safety and tolerability of escalating doses of VS-7375 in combination with pembrolizumab and to determine the recommended phase 2 dose (RP2Ds) in patients with advanced or metastatic NSCLC harboring KRAS G12D-mutation.

    Treatment: VS-7375 and Pembrolizumab

  • VS-7375 + Defactinib Dose EscalationTreatment being tested

    To characterize the safety and tolerability of escalating doses of VS-7375 in combination with defactinib and to determine the recommended phase 2 dose (RP2Ds) in patients with advanced or metastatic NSCLC harboring KRAS G12D-mutation.

    Treatment: VS-7375 and Defactinib

  • VS-7375 + Cetuximab Dose ExpansionTreatment being tested

    To evaluate the efficacy of VS-7375 in combination with cetuximab at the recommended phase 2 dose (RP2Ds) in patients with with advanced or metastatic CRC harboring KRAS G12D-mutation.

    Treatment: VS-7375 and Cetuximab

  • VS-7375 + Carboplatin/Pemetrexed/Pembrolizumab Dose ExpansionTreatment being tested

    To evaluate the efficacy of VS-7375 in combination with carboplatin/pemetrexed/pembrolizumab at the recommended phase 2 dose (RP2Ds) in patients with metastatic NSCLC harboring KRAS G12D-mutation.

    Treatment: VS-7375 and Carboplatin + Pemetrexed + Pembrolizumab

  • VS-7375 + Gemcitabine/Nab-Paclitaxel Dose ExpansionTreatment being tested

    To evaluate the efficacy of VS-7375 in combination with gemcitabine/nab-paclitaxel at the recommended phase 2 dose (RP2Ds) in patients with metastatic PDAC harboring KRAS G12D-mutation.

    Treatment: VS-7375 and Gemcitabine + Nab-paclitaxel

  • VS-7375 + Midazolam and Repaglinide Drug-Drug InteractionTreatment being tested

    To assess the drug-drug interaction of VS-7375 in combination with midazolam and repaglinide in patients with advanced or metastatic PDAC, NSCLC, and CRC harboring a KRAS G12D mutation.

    Treatment: VS-7375, Midazolam, and Repaglinide

  • VS-7375 Serial BiopsyTreatment being tested

    To characterize the preliminary anti-cancer activity of VS-7375 in participants with metastatic PDAC who have received 2 or 3 prior therapies, correlated with biopsy-obtained biomarkers.

    Treatment: VS-7375

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
A Phase 1/2, Open-label Study of VS-7375, a KRAS G12D (ON/OFF) Inhibitor, as Monotherapy and in Combination, in Patients With Advanced KRAS G12D-Mutated Solid Tumors
Plain-language title
Tests VS-7375 in adults with advanced solid tumors carrying a KRAS G12D mutationGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
10 November 2026